ZELRISTY
Live / Allowed — Published for opposition (as of 22 Oct 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 27 Mar 2026 filing date already counts against anyone who files later.
Record
- Serial number
- 99729374
- Mark type
- Word mark
- Filed
- 27 Mar 2026
- Published for opposition
- 11 Aug 2026
- Attorney of record
- John V. Hobgood, Esquire
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical and biological preparations based on base editing, base modification, nucleobase editing, nucleobase modification, nucleic acid editing, gene editing, gene modification, gene modulation, gene therapy, genome editing, genome modification, cell therapy, cellular modification, and tissue modification for use in human therapeutics for the treatment of Sickle Cell Disease
Owner
- Beam Therapeutics Inc., Cambridge, MA, US
- Beam Therapeutics Inc., Cambridge, MA, US
Board proceedings on this mark
- Extension of Time to Oppose No. 99729374 — Genzyme Corporation v. Beam Therapeutics Inc., filed 09 Sept 2026 (Terminated)
Prosecution history
- 21 Oct 2026 — EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
- 02 Oct 2026 — TEAS POST PUBLICATION AMENDMENT RECEIVED
- 02 Oct 2026 — TEAS POST PUBLICATION AMENDMENT RECEIVED
- 09 Sept 2026 — EXTENSION OF TIME TO OPPOSE RECEIVED
- 11 Aug 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 11 Aug 2026 — PUBLISHED FOR OPPOSITION
- 05 Aug 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 14 Jul 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 26 Jun 2026 — ASSIGNED TO EXAMINER
- 27 Mar 2026 — APPLICATION FILING RECEIPT MAILED
- 27 Mar 2026 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 27 Mar 2026 — NEW APPLICATION ENTERED